Pathway Labs Raises $8.5M Seed Round to Support EchoNext AI Tool Deployment

Why It Matters

The clearance gives clinicians a low‑cost, early‑detection method for conditions that normally require costly echocardiography, potentially reducing missed diagnoses and downstream expenses. Broad distribution through OpenEvidence may accelerate adoption and narrow AI‑driven care gaps between large health systems and smaller practices.

Key Takeaways

• EchoNext FDA‑cleared to flag six structural heart diseases from ECGs.
• Model trained on 700,000+ ECG‑echocardiogram pairs, 77% detection rate.
• Pathway Labs secured $8.5 million seed round for nationwide rollout.
• OpenEvidence reaches ~66% of U.S. physicians, expanding AI tool access.
• Early AI detection could prevent missed diagnoses and enable timely interventions.

Pulse Analysis

The cardiology market has long grappled with a diagnostic blind spot: routine electrocardiograms are inexpensive and widely available, yet they cannot reveal structural abnormalities that often require an echocardiogram. EchoNext bridges that gap by applying deep‑learning to ECG waveforms, flagging patients who likely need imaging. This approach mirrors how AI has transformed radiology, turning a simple, low‑cost test into a powerful screening tool that can triage patients before they reach more expensive, resource‑intensive procedures.

Performance data underscore EchoNext’s potential to reshape care pathways. In a 2025 Nature study, the algorithm identified 77% of structural heart disease cases across 3,200 ECGs, outpacing cardiologists’ 64% accuracy. Real‑world case reports, including a patient whose AI‑detected heart failure led to a life‑saving transplant, illustrate how earlier identification can alter treatment trajectories and reduce hospital readmissions. By prompting timely echocardiograms, the tool may lower overall cardiac care costs while improving outcomes for conditions such as valve disease, cardiomyopathy, and pulmonary hypertension.

Commercially, the partnership with OpenEvidence amplifies EchoNext’s reach. With roughly two‑thirds of U.S. physicians already logged into the platform, the AI biomarker can bypass traditional procurement delays that often confine advanced tools to academic centers. The $8.5 million seed infusion equips Pathway Labs to scale integration, support ongoing validation, and address equity concerns by making the technology accessible to community practices. As regulators become more comfortable with AI‑based diagnostics, EchoNext could set a precedent for rapid, scalable deployment of AI biomarkers across other disease domains.

Deal Summary

Pathway Labs, the company behind the FDA‑cleared EchoNext AI tool for detecting hidden structural heart disease, announced an $8.5 million seed round to fund research, development, and broader deployment across health systems. The round supports the partnership with OpenEvidence to bring the tool to U.S. physicians.